Morgan Stanley’s AgomAb Therapeutics NV AGMB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$68.2K Buy
6,146
+4,946
+412% +$64K ﹤0.01% 6465
2026
Q2
$15.6K Sell
1,200
-1,825
-60% -$20.5K ﹤0.01% 6903
2026
Q1
$31.7K Buy
+3,025
New +$42.8K ﹤0.01% 6570

Other funds holding AGMB

Morgan Stanley's AGMB Position: Q3 2026 in Review

Morgan Stanley increased its AgomAb Therapeutics NV (AGMB) stake by 412% in Q3 2026, buying an estimated $64K and bringing the position to 6,146 shares worth $68.2K. The position accounts for ﹤0.01% of the portfolio, ranked #6465.

Morgan Stanley first reported a position in AGMB in Q1 2026 and has held it in 3 quarters since. 25 funds tracked by Wall St. Rank hold AGMB as of Q3 2026.

  • Morgan Stanley held 6,146 shares of AgomAb Therapeutics NV worth $68.2K as of Q3 2026.
  • Morgan Stanley bought 4,946 AgomAb Therapeutics NV shares in Q3 2026, an estimated $64K.
  • AgomAb Therapeutics NV made up ﹤0.01% of Morgan Stanley's portfolio in Q3 2026, its #6465 holding.
  • Morgan Stanley first reported a position in AgomAb Therapeutics NV in Q1 2026 and has held it in 3 quarters since.
  • 25 funds tracked by Wall St. Rank held AgomAb Therapeutics NV as of Q3 2026.

Based on Morgan Stanley's 13F filing for Q3 2026, filed 13 Nov 2026.